{"id":"NCT01237223","sponsor":"Novartis","briefTitle":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","officialTitle":"An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2010-11-09","resultsPosted":"2012-06-13","lastUpdate":"2012-06-13"},"enrollment":1342,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"Aliskiren/Amlodipine 150/2.5 mg","otherNames":[]},{"type":"DRUG","name":"Aliskiren/amlodipine 150/5 mg","otherNames":[]},{"type":"DRUG","name":"Aliskiren 150 mg","otherNames":[]},{"type":"DRUG","name":"Amlodipine 2.5 mg","otherNames":[]},{"type":"DRUG","name":"Placebo of Aliskiren","otherNames":[]},{"type":"DRUG","name":"Placebo of Amlodipine","otherNames":[]},{"type":"DRUG","name":"Placebo of Aliskiren/amlodipine 150/2.5 mg","otherNames":[]},{"type":"DRUG","name":"Placebo of Aliskiren/amlodipine 150/5 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aliskiren 150 mg","type":"ACTIVE_COMPARATOR"},{"label":"Amlodipine 2.5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Amlodipine 5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Aliskiren/amlodipine 150/2.5 mg","type":"EXPERIMENTAL"},{"label":"Aliskiren/amlodipine 150/5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure \\[msDBP\\] ≥ 95 mmHg and \\< 110 mmHg and mean sitting systolic blood pressure \\[msSBP\\] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.","primaryOutcome":{"measure":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-5.21,"sd":0.69},{"arm":"Aliskiren 150 mg","deltaMin":-7.49,"sd":0.68},{"arm":"Amlodipine 2.5 mg","deltaMin":-9.46,"sd":0.68},{"arm":"Amlodipine 5 mg","deltaMin":-11.9,"sd":0.68},{"arm":"Aliskiren/Amlodipine 150/2.5 mg","deltaMin":-12.4,"sd":0.68},{"arm":"Aliskiren/Amlodipine 150/5 mg","deltaMin":-16.43,"sd":0.68}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":153},"commonTop":["Nasopharyngitis","Headache"]}}